160 related articles for article (PubMed ID: 15540536)
1. [Inflammation and diabetes].
Löbner K; Füchtenbusch M
MMW Fortschr Med; 2004 Sep; 146(35-36):32-3, 35-6. PubMed ID: 15540536
[TBL] [Abstract][Full Text] [Related]
2. [Chronic inflammation can cause type 2 diabetes].
Sjöholm A; Nyström T
Lakartidningen; 2004 May; 101(19):1716-21. PubMed ID: 15188586
[No Abstract] [Full Text] [Related]
3. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Schernthaner GH; Schernthaner G
Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
Nesto R
Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
[TBL] [Abstract][Full Text] [Related]
6. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes.
Ndisang JF; Jadhav A
Diabetes Obes Metab; 2013 Nov; 15(11):1029-39. PubMed ID: 23731386
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
8. [Obesity and inflammation].
Recasens M; Ricart W; Fernández-Real JM
Rev Med Univ Navarra; 2004; 48(2):49-54. PubMed ID: 15382613
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic options for metabolic syndrome in obese patients].
Carella AM; Conte M
Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
11. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.
Chu JW; Abbasi F; Lamendola C; McLaughlin T; Reaven GM; Tsao PS
Diab Vasc Dis Res; 2005 Feb; 2(1):37-41. PubMed ID: 16305071
[TBL] [Abstract][Full Text] [Related]
13. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Petersen JL; McGuire DK
Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
[TBL] [Abstract][Full Text] [Related]
14. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
[TBL] [Abstract][Full Text] [Related]
15. [Is type-2 diabetes mellitus preventable?].
Jermendy G
Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
[TBL] [Abstract][Full Text] [Related]
16. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Mourad AA; Heeba GH; Taye A; El-Moselhy MA
Fundam Clin Pharmacol; 2013 Oct; 27(5):489-97. PubMed ID: 22712525
[TBL] [Abstract][Full Text] [Related]
17. Inflammation and the etiology of type 2 diabetes.
Sjöholm A; Nyström T
Diabetes Metab Res Rev; 2006; 22(1):4-10. PubMed ID: 15991254
[TBL] [Abstract][Full Text] [Related]
18. Hyperinsulinemia, insulin resistance, and hypertension.
Bönner G
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S39-49. PubMed ID: 7898093
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.
Dandona P; Aljada A; Chaudhuri A; Mohanty P; Garg R
Circulation; 2005 Mar; 111(11):1448-54. PubMed ID: 15781756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
